Clinical Trial Update: Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

View source ↗

Summary

A completed postmarketing surveillance study evaluating Berotec N 100 µg Metered-dose Inhaler for chronic obstructive respiratory disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Berotec N 100 µg Metered-dose Inhaler (fenoterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Status: COMPLETED